Patents by Inventor Kathleen Sereda Glaub

Kathleen Sereda Glaub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH
    Publication number: 20220143015
    Abstract: Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 12, 2022
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Kathleen Sereda Glaub, Michael M. Kitt, Steven Smith
  • Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough
    Patent number: 11260056
    Abstract: Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: March 1, 2022
    Assignee: AFFERENT PHARMACEUTICALS, INC.
    Inventors: Anthony P. Ford, Kathleen Sereda Glaub, Michael M. Kitt, Steven Smith
  • DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH
    Publication number: 20180280388
    Abstract: Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.
    Type: Application
    Filed: September 23, 2016
    Publication date: October 4, 2018
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Kathleen Sereda Glaub, Michael M. Kitt, Steven Smith